Viewing Study NCT04869358

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:07 AM
Ignite Modification Date: 2026-02-20 @ 10:10 PM
Study NCT ID: NCT04869358
Status: COMPLETED
Last Update Posted: 2025-05-16
First Post: 2021-04-29
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Relapsing Multiple Sclerosis View
Keywords:

Keywords

Keyword Brief Keyword Text View
None COVID-19 View
None SARS-CoV-2 mRNA vaccine View
None immune response View
None Ofatumumab View
None Relapsing Multiple Sclerosis View
None RMS View
None adult View
None MS View